Merck Q2 sales soar on back of COVID drug Lagevrio, Keytruda; raises/narrows FY22 outlook

Jul. 28, 2022 7:38 AM ETMerck & Co., Inc. (MRK)By: Ravikash, SA News Editor1 Comment

Merck Research Laboratories sleek, all-glass headquarters building in Silicon Valley. Merck Co. Inc. is an American multinational pharmaceutical company

Michael Vi

Merck's (NYSE:MRK) Q2 sales grew 28% Y/Y on the back of COVID therapy Lagevrio and blockbuster cancer drug Keytruda, and the company also raised and narrowed its FY22 outlook.

Q2 total sales grew +28% Y/Y to $14.59B.

COVID pill Lagevrio (molnupiravir), developed

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.